iPS cell

What are iPS cells?

iPS cells (induced pluripotent stem cells) are pluripotent stem cells produced by introducing reprogramming factors (such as Oct3/4, Sox2, Klf4, and c-Myc) into somatic cells.Can be used as an autologous or allogeneic cell sourcepoints are a major feature. Compared to ES cells, they have lower ethical hurdles and high compatibility with genome editing such as HLA homo-donors and immune-evasive iPS cells, driving their application in drug discovery and regenerative medicine. They are expected to be deployed into a wide range of tissue regeneration and cell therapy products, including cardiomyocytes, neurons, retinas, livers, and immune cells (iNK/iT).

Representative examples of iPS cells

iPS cell-derived retinal pigment epithelium (RPE) cells/sheet

iPS cell-derived retinal pigment epithelium (RPE) cells and sheets are pioneering examples of iPS cell-applied products targeting conditions such as age-related macular degeneration.Local transplantation of RPE cells in suspension or sheet formby evaluating localization and tissue engraftment. It is also positioned as a prototype for evaluation methods for regenerative medicine products, including surgical transplantation techniques.

iPS cell-derived cardiomyocytes and myocardial sheets

iPS cell-derived cardiomyocytes and myocardial sheets are myocardial regeneration approaches targeting severe heart failure. In addition to confirming functional beating and electrophysiological coupling (syncytium formation),It is important to evaluate electrophysiological safety, such as ventricular arrhythmia (arrhythmogenic risk).It is. Applications to three-dimensional tissues and parenchymal organs, such as myocardial sheets and myocardial spheroids, are currently advancing.

iPSC-derived dopaminergic neural progenitor cells

iPS cell-derived dopaminergic neural progenitors are a therapeutic approach using intracerebral transplantation for Parkinson's disease. In addition to long-term survival, axonal extension, and functional recovery through dopamine release after transplantation,Rigorous safety monitoring, such as for teratomas and graft regrowthis important. It is being researched as a cellular product suitable for local administration into the central nervous system (CNS).

Important challenges in iPS cell development

Risk of tumorigenesis (teratoma/malignant tumor) due to the residual presence of undifferentiated iPS cells (positive for TRA-1-60/SSEA-4, etc.) and accumulation of mutations

In iPS cell-derived products, if undifferentiated iPS cells (such as TRA-1-60 and SSEA-4 positive) remain in the final product, there is a risk of teratoma formation after transplantation. Furthermore, long-term cultuRisk of abnormal proliferation or malignant transformation due to TP53 mutations associated with cell culture or genome editingis also generated. It is important to detect and eliminate trace amounts of abnormal cells from a large population of cells.

Ensuring heterogeneity in differentiation induction efficiency and maturity into target cells, as well as batch-to-batch comparability/homogeneity (QA/QC)

Induction of differentiation from iPS cells into target cells is complex, and may result in the contamination of immature progenitor cells or unintended heterogeneous cells (off-target lineages).Quantifying the maturity required for the target organization to exhibit necessary functionsand it is important to suppress variations between lots. Therefore, the establishment of QA/QC using differentiation efficiency and cell characteristics as indicators is required.

Long-term in vivo persistence, biodistribution, and allogeneic immune rejection

With iPS cell-derived products, on the other hand, it is necessary to confirm whether they can properly engraft at the target site after administration and maintain their function over the long term.Evaluation of the risk of migration to other organs via the circulatory system, embolism, and ectopic engraftment.is required. Furthermore, for allogeneic products, an additional challenge is to appropriately evaluate rejection reactions caused by the recipient's immunity in non-clinical models.

Non-clinical evaluation required for iPS cell development

Rating 1: "High-sensitivity in vitro undifferentiated cell detection & ultra-long-term in vivo immunodeficient animal transplantation evaluation" that eliminates tumorigenic risk to the absolute limit

In iPS cell-derived products, the tumorigenicity risk due to residual undifferentiated cells must be strictly evaluated.Detection of trace amounts of undifferentiated cells using ddPCR, qRT-PCR, flow cytometry, etc.Then, we will confirm the presence or absence of tumor formation in a long-term transplantation study using severely immunodeficient mice. It is important to combine the in vitro and in vivo results to comprehensively evaluate safety.

Score 2: "Single-Cell RNA-seq & Spatial Transcriptomics Analysis" visualizing differentiation maturity and cell population homogeneity

For iPS cell-derived products, it is important to evaluate the diversity of the cell population and the contamination of immature or foreign cells on a per-cell basis.Visualization of differentiation maturity and unintended lineage contamination using Single-Cell RNA-seq or Spatial Transcriptomicsand evaluate product homogeneity. We analyze the manufacturing process and final products, and utilize this analysis to establish QC indicators and confirm batch-to-batch consistency.

Rating 3: "Non-invasive in vivo imaging & Biodistribution (BD) quantitative assay" for tracking cell migration, localization, and engraftment in vivo

For iPS cell-derived products, it is important to evaluate whether the administered cells properly engraft into the target tissue and do not migrate to other organs.Tracking the biodistribution, engraftment, and clearance of cells over time by combining non-invasive in vivo imaging with tissue-specific quantification by ddPCR.I will. This makes it possible to evaluate risks such as ectopic accumulation and embolization.

Rating 4: Allogeneic Transplantation in "Immune Rejection & Tissue Engraftment & Electrophysiological & Tissue Functional Compatibility Assay"

For allogeneic iPS cell-derived products, it is necessary to evaluate the risks of cell elimination and engraftment failure due to immune rejection.Confirming engraftment and survival in immune-reconstituted mice or allogeneic large animal models, MEA or patch-clamp analysis is used to evaluate electrophysiological compatibility with the host tissue. In cardiomyocytes in particular, it is also important to check for the risk of arrhythmia induction.

Key points when choosing a contract research organization (CRO) for non-clinical studies

While regenerative medicine and cell therapies using iPS cells are advancing toward practical application in a wide range of fields such as cardiac muscle, nerves, and the retina, challenges remain, including tumorigenicity, cell homogeneity, biodistribution, and immune rejection. For future commercialization, it is important to establish a non-clinical testing system capable of appropriately evaluating these factors and to select a strategic CRO with the necessary expertise and track record.